Investigating how immune responses affect pancreatic cancer growth
Role of type 2 immune response in pancreatic cancer tumorigenesis
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-11052886
This study is looking at how certain immune responses might help pancreatic cancer grow and resist treatment, with the goal of finding new ways to improve care for patients with this tough disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-11052886 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of type 2 immune responses in the development of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The study examines how certain immune cells and cytokines in the tumor microenvironment contribute to tumor growth and resistance to treatment. By exploring the interactions between cancer cells and immune cells, the research aims to identify new therapeutic strategies that could improve patient outcomes. The approach includes both genetic and pharmacological methods to inhibit specific immune signaling pathways that support tumor development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of cancer or those without pancreatic cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance survival rates for patients with pancreatic cancer.
How similar studies have performed: While this research explores novel interactions in pancreatic cancer, similar approaches targeting immune responses have shown promise in other cancer types, indicating potential for success.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEY, PRASENJIT — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: DEY, PRASENJIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.